Type 2 Diabetes without CKD: GREEN preferred SGLT2i. Also indicated for use as per NICE TA336 and NICE TA390 for type 2 diabetes : in combination with other glucose-lowering agents and for use as monotherapy. See local type 2 diabetes guidance. (Decision date -Dec 2022)
Type 2 Diabetes with CKD: GREEN - as per NICE NG28 and NG203, for adults with CKD and type 2 diabetes, in additions to an ACEI or ARB at an optimised dose. (Decision date - Sep 2021, updated Dec 2021, further update Dec 2022)
GREEN consultant/specialist initiation & stabilisation - NICE TA773 for treating chronic heart failure with reduced ejection fraction. (Decision date - April 2022)
GREEN after Consultant/Specialist recommendation - NICE TA929 Empagliflozin for treating symptomatic chronic heart failure with preserved or mildly reduced ejection fraction in adults (Decision - December 2023)
GREEN: NICE TA942 - for treating chronic kidney disease (CKD). Empagliflozin is recommended as an option only if: